Preclinical and exploratory human studies of novel ⁶⁸Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers.

ABSTRACT:

Purpose

While TIGIT has been propelled as a next-generation target in cancer immunotherapy, anti-TIGIT therapy seems to be promising for a fraction of patients in clinical trials. Therefore, patient stratification is critical for this therapy, which could benefit from a whole-body, non-invasive, and quantitative evaluation of TIGIT expression in cancers. In this study, a ⁶⁸Ga-labeled D-peptide antagonist, ⁶⁸Ga-GP12, was developed and validated for PET imaging of TIGIT expression in vitro, in vivo, and in an exploratory human study.

Methods

The D-enantiomer peptide antagonists were modified and radiolabeled with ⁶⁸Ga. In vitro binding assays were performed in human peripheral blood mononuclear cells (PBMCs) to assess their affinity and specifi

SUBMITTER: Wang X 

PROVIDER: S-EPMC8761874 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature